James Chih-Hsin Yang - Articles and news items

Boehringer Ingelheim logo

New efficacy and safety data adds to evidence suppoith afatinib*(GIOTRIF®) in Asian and non-Asian lung cancer patients

Industry news / 27 October 2013 / Boehringer Ingelheim

“The new sub-analysis confirms the consistent safety profile of afatinib in Asian patients…”

Boehringer Ingelheim logo

Afatinib* shows benefits for EGFR mutation positive non-small cell lung cancer patients across various efficacy endpoints

Industry news, News / 1 August 2013 / Boehringer Ingelheim

Data from the LUX-Lung clinical trial programme…

Boehringer Ingelheim logo
Boehringer Ingelheim logo

Afatinib* delivers unprecedented first line efficacy in patients with EGFR mutation positive lung cancer in registration trial

Industry news, News / 4 June 2012 / Boehringer Ingelheim

LUX-Lung 3 results highlighted at the official ASCO Press Conference…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+